{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-016454","form_type":"8-K","ticker":"GALT","cik":"0001133416","company_name":"GALECTIN THERAPEUTICS INC","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.484492+00:00","generated_at":"2026-06-04T05:12:00.887954+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galectin Therapeutics reports FY2023 net loss of $44.8M; cash runway through March 2025","bullets":["Net loss applicable to common stockholders of $44.8M ($0.74/share) vs $38.9M ($0.65/share) in FY2022.","Cash and equivalents $25.7M at Dec 31; plus $20M available credit line and new $10M facility from chairman.","NAVIGATE Phase 2b/3 trial for belapectin in MASH cirrhosis fully enrolled (357 patients); interim analysis readout expected Q4 2024.","Appointed Benjamin S. Carson, Sr., M.D. to Board of Directors.","Fourth DSMB meeting authorized continuation of NAVIGATE trial without modifications."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-016454","json":"https://secwatch.observer/filing/0001140361-24-016454.json","markdown":"https://secwatch.observer/filing/0001140361-24-016454.md","text":"https://secwatch.observer/filing/0001140361-24-016454.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/0001140361-24-016454-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/ef20025022_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:12:00.887954+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bfc747df69883ca390274febb61cb08bfa1b7c33","claim":"GALECTIN THERAPEUTICS INC reported the year ended December 31, 2023 results: net income net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, EPS $(0.74).","evidence_excerpt":"For the year ended December 31, 2023, the Company reported a net loss applicable to common stockholders of $44.8 million, or ($0.74) per share, compared to a net loss applicable to common stockholders of $38.9 million, or ($0.65) per share for the year ended December 31, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1133416/000114036124016454/0001140361-24-016454-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Net income","value":"net loss applicable to common stockholders of $44.8 million, or ($0.74) per share"},{"label":"EPS","value":"$(0.74)"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}